MCTA Charming Medical Ltd Annual reports only
Services-Misc Health & Allied Services, NEC · SEC CIK 2035992
Financial factors as of 2026-03-31 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-22.7%
TTM net income YoY-101.9%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin99.3%
Operating margin-0.6%
Net margin-0.5%
FCF margin-32.4%
EBITDA margin3.9%
Returns
ROE-0.9%
ROA-0.3%
ROIC (approx.)-34.1%
Asset turnover0.63x
Leverage & solvency
Liabilities / assets47.5%
Debt / equity0.07x
Current ratio1.89x
Interest coverage-1.85x
Cash quality & payout
Operating cash flow / net income53.69x
Accruals ratio15.7%
Payout ratio—
Capex / revenue7.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $4.81M | $6.22M | $6.02M |
| Cost of revenue | $35,221 | $15,514 | $11,294 |
| Gross profit | $4.77M | $6.21M | $6.00M |
| Operating income | -$29,237 | $1.39M | $1.01M |
| Interest expense | $15,799 | $20,874 | $26,051 |
| Pretax income | $133,466 | $1.44M | $1.00M |
| Income tax | $156,114 | $236,082 | $181,751 |
| Net income | -$22,648 | $1.20M | $777,811 |
| EBITDA | $186,837 | $1.65M | $1.40M |
| EPS (basic) | 0.00 | 0.08 | 0.05 |
| EPS (diluted) | 0.00 | 0.08 | 0.05 |
| Weighted avg. shares (diluted) | 16.15M | 15.34M | 15.34M |
| Balance sheet | |||
| Cash & equivalents | $4.70M | $816,771 | $2.10M |
| Receivables | $201,477 | $395,901 | — |
| Inventory | $25,623 | $26,797 | — |
| Current assets | $8.17M | $3.37M | — |
| PP&E, net | $606,901 | $500,053 | — |
| Total assets | $9.87M | $5.36M | — |
| Current liabilities | $4.33M | $4.95M | — |
| Short-term debt | $185,799 | $314,226 | — |
| Long-term debt | $185,799 | — | — |
| Total debt | $371,598 | — | — |
| Total liabilities | $4.69M | $5.31M | — |
| Shareholders' equity | $5.18M | $49,243 | -$1.15M |
| Net debt | -$4.33M | — | — |
| Cash flow statement | |||
| Operating cash flow | -$1.22M | $425,888 | $295,429 |
| Capital expenditure | $339,560 | $287,527 | $210,598 |
| Free cash flow | -$1.56M | $138,361 | $84,831 |
| Investing cash flow | -$179,015 | -$2.23M | -$210,598 |
| Financing cash flow | $5.29M | $521,303 | $100,145 |
| Depreciation & amortization | $216,074 | $263,454 | $391,704 |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.